問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberBRII-179-835-001

2021-03-01 - 2023-12-31

Phase II

Terminated5

ICD-10K71.0

Toxic liver disease with cholestasis

ICD-10K71.10

Toxic liver disease with hepatic necrosis, without coma

ICD-10K71.11

Toxic liver disease with hepatic necrosis, with coma

ICD-10K71.2

Toxic liver disease with acute hepatitis

ICD-10K71.3

Toxic liver disease with chronic persistent hepatitis

ICD-10K71.4

Toxic liver disease with chronic lobular hepatitis

ICD-10K71.50

Toxic liver disease with chronic active hepatitis without ascites

ICD-10K71.51

Toxic liver disease with chronic active hepatitis with ascites

ICD-10K71.6

Toxic liver disease with hepatitis, not elsewhere classified

ICD-10K71.7

Toxic liver disease with fibrosis and cirrhosis of liver

ICD-10K71.8

Toxic liver disease with other disorders of liver

ICD-10K71.9

Toxic liver disease, unspecified

ICD-10K75.2

Nonspecific reactive hepatitis

ICD-10K75.3

Granulomatous hepatitis, not elsewhere classified

ICD-10K75.81

Nonalcoholic steatohepatitis (NASH)

ICD-10K75.89

Other specified inflammatory liver diseases

ICD-10K75.9

Inflammatory liver disease, unspecified

ICD-10K76.4

Peliosis hepatis

ICD-9573.3

Hepatitis, unspecified

  • Trial Applicant

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2025/08/20

Investigators and Locations

Principal Investigator Chun-Jen Liu

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 胡琮輝

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 徐友春

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Cheng-Yuan Peng

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Chia-Yen Dai

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    25 participants

  • Global

    110 participants